[1] NALDINI L.Gene therapy returns to centre stage[J].Nature,2015,526(7573):351
[2] COLLINS M,THRASHER A.Gene therapy:progress and predictions[J].Proc Biol Sci,2015,282(1821):20143003
[3] KUMAR SR,MARKUSIC DM,BISWAS M,et al.Clinical development of gene therapy:results and lessons from recent successes[J].Mol Ther Methods Clin Dev,2016,3:16034
[4] LUKASHEV AN,ZAMYATNIN AA Jr.Viral vectors for gene therapy:current state and clinical perspectives[J].Biochemistry(Mosc),2016,81(7):700
[5] HOY SM.Onasemnogene abeparvovec:first global approval[J].Drugs,2019,79(4):1255
[6] 李永红,毕华,史新昌,等.人用基因治疗制品生产和质量控制的通用性技术要求[J].中国新药杂志,2018,27(21):2482 LI YH,BI H,SHI XC,et al.General technical requirements for production and quality control of human gene therapy products[J].Chin J New Drug,2018,27(21):2482
[7] 王军志生物技术药物研究开发和质量控制[M]第3版.北京:科学出版社,2018:876 WANG JZ.Research,Development and Quality Control of Biopharmaceuticals[M].3rd Ed.Beijing:Science Press,2018:876
[8] MITTEREDER N,MARCH KL,TRAPNELL BC.Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy[J].J Virol,1996,70(11):7498
[9] WHITFIELD RJ,BATTOM SE,BARUT M,et al.Rapid high-performance liquid chromatographic analysis of adenovirus type 5 particles with a prototype anion-exchange analytical monolith column[J].J Chromatogr A,2009,1216(13):2725
[10] GRIMM D,KERN A,PAWLITA M,et al.Titration of AAV-2 particles via a novel capsid ELISA:packaging of genomes can limit production of recombinant AAV-2[J].Gene Ther,1999,6(7):1322
[11] LOGAN AC,NIGHTINGALE SJ,HAAS DL,et al.Factors influencing the titer and infectivity of lentiviral vectors[J].Hum Gene Ther,2004,15(10):976
[12] ROSSI CA,KEARNEY BJ,OLSCHNER SP,et al.Evaluation of ViroCyt? Virus Counter for rapid filovirus quantitation[J].Viruses,2015,7(3):857
[13] KRAMBERGER P,CIRINGER M,?TRANCAR A,et al.Evaluation of nanoparticle tracking analysis for total virus particle determination[J].Virol J,2012,9:265
[14] WEATHERALL E,WILLMOTT GR.Applications of tunable resistive pulse sensing[J].Analyst,2015,140(10):3318
[15] BOUSSE T,SHORE DA,GOLDSMITH CS,et al.Quantitation of influenza virus using field flow fractionation and multi-angle light scattering for quantifying influenza A particles[J].J Virol Methods,2013,193(2):589
[16] MA L,BLUYSSEN HA,DE RAEYMAEKER M,et al.Rapid determination of adenoviral vector titers by quantitative real-time PCR[J].J Virol Methods,2001,93(1-2):181
[17] WERLING NJ,SATKUNANATHAN S,THORPE R,et al.Systematic comparison and validation of quantitative real-time PCR methods for the quantitation of adeno-associated viral products[J].Hum Gene Ther Methods,2015,26(3):82
[18] GRIEGER JC,CHOI VW,SAMULSKI RJ.Production and characterization of adeno-associated viral vectors[J].Nat Protoc,2006,1(3):1412
[19] SANMIGUEL J,GAO G,VANDENBERGHE LH.Quantitative and digital droplet-based AAV genome titration[J].Methods Mol Biol,2019,1950:51
[20] LABARRE DD,LOWY RJ.Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays[J].J Virol Methods,2001,96(2):107
[21] MURAKAMI P,HAVENGA M,FAWAZ F,et al.Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches[J].J Virol,2004,78(12):6200
[22] WANG F,PUDDY AC,MATHIS BC,et al.Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy:toward a universal method for the facile quantitation of virus and vector potency[J].Vaccine,2005,23(36):4500
[23] AZIZI A,TANG M,GISONNI-LEX L,et al.Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach[J].BMC Microbiol,2013,13:284
[24] ZEN Z,ESPINOZA Y,BLEU T,et al.Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events[J].Hum Gene Ther,2004,15(7):709
[25] SALVETTI A,ORèVE S,CHADEUF G,et al.Factors influencing recombinant adeno-associated virus production[J].Hum Gene Ther,1998,9(5):695
[26] BARDE I,SALMON P,TRONO D.Production and titration of lentiviral vectors[J].Curr Protoc Neurosci,2010,53(1):4.21.1
[27] 刁勇,王启钊,吕颖慧,等.重组腺相关病毒基因药物的病毒滴度定量测定[J].中国新药与临床杂志,2010,29(10):728 DIAO Y,WANG QZ Lü YH,et al.Biological assay of recombinant adeno-associated virus gene medicine[J].Chin J New Drugs Clin Rem,2010,29(10):728
[28] PALMER DJ,NG P.Physical and infectious titers of helper-dependent adenoviral vectors:a method of direct comparison to the adenovirus reference material[J].Mol Ther,2004,10(4):792
[29] D'COSTA S,BLOUIN V,BROUCQUE F,et al.Practical utilization of recombinant AAV vector reference standards:focus on vector genomes titration by free ITR qPCR[J].Mol Ther Methods Clin Dev,2016,5:16019
[30] BLOTTA I,PRESTINACI F,MIRANTE S,et al.Quantitative assay of total dsDNA with PicoGreen reagent and real-time fluorescent detection[J].Ann Ist Super Sanita,2005,41(1):119
[31] ZHOU Y,MAO S,LI Y,et al.Improved fluorometric DNA determination based on the interaction of the DNA/polycation complex with Hoechst 33258[J].Microchim Acta,2004, 144(1-3):191
[32] MOTAé,SOUSA ?,?ERNIGOJ U,et al.Rapid quantification of supercoiled plasmid deoxyribonucleic acid using a monolithic ion exchanger[J].J Chromatogr A,2013,1291:114
[33] FAWAZ FS,ELSHEIKH MA,OGAWA Y,et al.A potency assay for a replication incompetent adenovirus type 5 carrying a human fgf-4 gene[J].Anal Biochem,2005,342(1):34
[34] ROMAN AJ,BOYE SL,ALEMAN TS,et al.Electroretinographic analyses of Rpe65-mutant rd12 mice:developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis[J].Mol Vis,2007,13:1701
[35] WAERNER T,GIRSCH T,VARGA S,et al.A receptor-binding-based bioassay to determine the potency of a plasmid biopharmaceutical encoding VEGF-C[J].Anal Bioanal Chem,2007,389(7-8):2109
[36] HUANG L,CHIN E,CHIANG YL.Development of potency assays for a plasmid containing vascular endothelial growth factor 2[J].Electron J Biotechnol,2010,13(1):1
[37] YAMAGUCHI T,UCHIDA E.Oncolytic virus:regulatory aspects from quality control to clinical studies[J].Curr Cancer Drug Targets,2018,18(2):202
[38] WANG X,MORGAN DM,WANG G,et al.Residual DNA analysis in biologics development:review of measurement and quantitation technologies and future directions[J].Biotechnol Bioeng,2012,109(2):307
[39] WRIGHT JF.Manufacturing and characterizing AAV-based vectors for use in clinical studies[J].Gene Ther,2008,15(11):840
[40] THORNE BA,QUIGLEY P,NICHOLS G,et al.Characterizing clearance of helper adenovirus by a clinical rAAV1 manufacturing process[J].Biologicals,2008,36(1):7
[41] YE GJ,SCOTTI MM,LIU J,et al.Clearance and characterization of residual HSV DNA in recombinant adeno-associated virus produced by an HSV complementation system[J].Gene Ther,2011,18(2):135
[42] ALLAY JA,SLEEP S,LONG S,et al.Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial[J].Hum Gene Ther,2011,22(5):595
[43] WRIGHT JF.Product-related impurities in clinical-grade recombinant AAV vectors:characterization and risk assessment[J].Biomedicines,2014,2(1):80
[44] SCHN?DT M,BüNING H.Improving the quality of adeno-associated viral vector preparations:the challenge of product-related impurities[J].Hum Gene Ther Methods,2017,28(3):101
[45] RODRIGUES GA,SHALAEV E,KARAMI TK,et al.Pharmaceutical development of AAV-based gene therapy products for the eye[J].Pharm Res,2018,36(29):1
[46] ALLAY JA,SLEEP S,LONG S,et al.Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial[J].Hum Gene Ther,2011,22(5):595
[47] TAKAHASHI E,COHEN SL,TSAI PK,et al.Quantitation of adenovirus type 5 empty capsids[J].Anal Biochem,2006,349(2):208
[48] BURNHAM B,NASS S,KONG E,et al.Analytical ultracentrifugation as an approach to characterize recombinant adeno-associated viral vectors[J].Hum Gene Ther Methods,2015,26(6):228
[49] YANG X,AGARWALA S,RAVINDRAN S,et al.Determination of particle heterogeneity and stability of recombinant adenovirus by analytical ultracentrifugation in CsCl gradients[J].J Pharm Sci,2008,97(2):746
[50] PIERSON EE,KEIFER DZ,ASOKAN A,et al.Resolving adeno-associated viral particle diversity with charge detection mass spectrometry[J].Anal Chem,2016,88(13):6718
[51] KONZ JO,LEE AL,LEWIS JA,et al.Development of a purification process for adenovirus:controlling virus aggregation to improve the clearance of host cell DNA[J].Biotechnol Prog,2005,21(2):466
[52] WRIGHT JF,LE T,PRADO J,et al.Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation[J].Mol Ther,2005,12(1):171
[53] KAHLER AM,CROMEANS TL,METCALFE MG,et al.Aggregation of adenovirus 2 in source water and impacts on disinfection by chlorine[J].Food Environ Virol,2016,8(2):148
[54] MCEVOY M,RAZINKOV V,WEI Z,et al.Improved particle counting and size distribution determination of aggregated virus populations by asymmetric flow field-flow fractionation and multiangle light scattering techniques[J].Biotechnol Prog,2011,27(2):547
[55] SHIH SJ,YAGAMI M,TSENG WJ,et al.Validation of a quantitative method for detection of adenovirus aggregation[J].Bioprocess J,2011,9(2):25
[56] KRAMBERGER P,CIRINGER M,?TRANCAR A,et al.Evaluation of nanoparticle tracking analysis for total virus particle determination[J].Virol J,2012,265:1
[57] SMITH CR,DEPRINCE RB,DACKOR J,et al.Separation of topological forms of plasmid DNA by anion-exchange HPLC:shifts in elution order of linear DNA[J].J Chromatogr B Analyt Technol Biomed Life Sci,2007,854(1-2):121
[58] SCHMIDT T,FRIEHS K,SCHLEEF M,et al.Quantitative analysis of plasmid forms by agarose and capillary gel electrophoresis[J].Anal Biochem,1999,274(2):235
[59] CHUAH MK,COLLEN D,VANDENDRIESSCHE T.Biosafety of adenoviral vectors[J].Curr Gene Ther,2003,3(6):527
[60] SCHALK JA,DE VRIES CG,ORZECHOWSKI TJ,et al.A rapid and sensitive assay for detection of replication-competent adenoviruses by a combination of microcarrier cell culture and quantitative PCR[J].J Virol Methods,2007,145(2):89
[61] FALLAUX FJ,BOUT A,van der VELDE I,et al.New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses[J].Hum Gene Ther,1998,9(13):1909
[62] MARZIO G,KERKVLIET E,BOGAARDS JA,et al.A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells[J].Vaccine,2007,25(12):2228
[63] ZHANG WW,KOCH PE,ROTH JA.Detection of wild-type contamination in a recombinant adenoviral preparation by PCR[J].Biotechniques,1995,18(3):444
[64] PUNTEL M,CURTIN JF,ZIRGER JM,et al.Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo,using quantitative TaqMan real-time polymerase chain reaction[J].Hum Gene Ther,2006,17(5):531
[65] SCHALK JA,de VRIES CG,ORZECHOWSKI TJ,et al.A rapid and sensitive assay for detection of replication-competent adenoviruses by a combination of microcarrier cell culture and quantitative PCR[J].J Virol Methods,2007,145(2):89
[66] LI F,FENG L,LIU Y,et al.An integrated cell culture and quantitative polymerase chain reaction technique for determining titers of functional and infectious adenoviruses[J].Anal Biochem,2009,391(2):157
[67] CHONG H,STARKEY W,VILE RG.A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector,one of the packaging constructs,and endogenous retroviral sequences[J].J Virol,1998,72(4):2663
[68] DONAHUE RE,KESSLER SW,BODINE D,et al.Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer[J].J Exp Med,1992,176(4):1125
[69] LONG Z,LI LP,GROOMS T,et al.Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells[J].Hum Gene Ther,1998,9(8):1165
[70] MARTINEAU D,KLUMP WM,MCCORMACK JE,et al.Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus[J].Hum Gene Ther,1997,8(10):1231
[71] HASHIMOTO-GOTOH A,YOSHIKAWA R,MIYAZAWA T.Comparison between S+L-assay and LacZ marker rescue assay for detecting replication-competent gammaretroviruses[J].Biologicals,2015,43(5):363
[72] ROTHE M,MODLICH U,SCHAMBACH A.Biosafety challenges for use of lentiviral vectors in gene therapy[J].Curr Gene Ther,2013,13(6):453
[73] CORNETTA K,YAO J,JASTI A,et al.Replication-competent lentivirus analysis of clinical grade vector products[J].Mol Ther,2011,19(3):557
[74] SKRDLANT LM,ARMSTRONG RJ,KEIDAISCH BM,et al.Detection of replication competent lentivirus using a qPCR assay for VSV-G[J].Mol Ther Methods Clin Dev,2018,8:1
[75] SASTRY L,XU Y,DUFFY L,et al.Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection[J].Hum Gene Ther,2005,16(10):1227
[76] MARCUCCI KT,JADLOWSKY JK,HWANG WT,et al.Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients[J].Mol Ther,2018,26(1):269
[77] WORKING PK,LIN A,BORELLINI F.Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses[J].Oncogene,2005,24(52):7792
[78] SHIH SJ,MIYASHITA-LIN E,TSENG WJ,et al.Use of a bioamplification assay to detect nonselective recombinants and assess the genetic stability of oncolytic adenoviruses[J].Hum Gene Ther,2010,21(12):1707
